Therapeutics, Bristol-Myers Squibb, Lexicon Pharmaceuticals, and Pfizer are among the other providers.
Santhera Pharmaceuticals, PTC Therapeutics, BioMarin Pharmaceutical, Sarepta Therapeutics, and Eli Lilly are among the leading companies in the global muscular dystrophy therapy market. Emflaza, an oral corticosteroid approved and launched in 2017, has been demonstrated to be highly successful in helping patients develop strength and walk again. Acceleron Pharma, Capricor Therapeutics, Bristol-Myers Squibb, Lexicon Pharmaceuticals, and Pfizer are among the other providers.
